Showing results (221-230 of 258) with videos related to
Sort By:
Pageof 26
The New England Journal of Medicine|November 21, 2017
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung CancerJean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2011
EGFR L858R mutation and polymorphisms of genes related to estrogen biosynthesis and metabolism in never-smoking female lung adenocarcinoma patientsShi-Yi Yang, Tsung-Ying Yang, Kun-Chieh Chen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 23, 2011
Epidermal growth factor receptor mutation status in stage I lung adenocarcinoma with different image patternsKuo-Hsuan Hsu, Kun-Chieh Chen, Tsung-Ying Yang, et al.Cancer Discovery|April 11, 2022
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsMengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, et al.International Journal of Cancer|May 11, 2012
EGFR exon 19 in-frame deletion and polymorphisms of DNA repair genes in never-smoking female lung adenocarcinoma patientsShi-Yi Yang, Tsung-Ying Yang, Yao-Jen Li, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 11, 2015
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I MutationsChao-Hua Chiu, Cheng-Ta Yang, Jin-Yuan Shih, et al.Cancer Research|May 25, 2013
Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokersXifeng Wu, Liang Wang, Yuanqing Ye, et al.The Lancet. Oncology|January 16, 2015
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsJames Chih-Hsin Yang, Yi-Long Wu, Martin Schuler, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 21, 2022
Recalibrating Risk Prediction Models by Synthesizing Data Sources: Adapting the Lung Cancer PLCO Model for TaiwanLi-Hsin Chien, Tzu-Yu Chen, Chung-Hsing Chen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 TrialJames Chih-Hsin Yang, D Ross Camidge, Cheng-Ta Yang, et al.Pageof 26